Furthermore, gastrointestinal disturbances, including diarrhea and nausea are non hematologic group of side effects commonly reported with proteasome inhibitors.[1] Additionally, cardiovascular toxicity may be an outcome of Carfilzomib treatment due to the effects on proteasomes in the myocardium.[21] Thus, patient evaluation and risk assessment prior to initiation of therapy with carfilzomib is crucial.[24]